Drug Analogue Screening & Forecasting Tool (U.S. Market Data)
The two most popular methods for conducting forecasting
studies for pipeline drugs are by Epidemiology (patient) based
forecasting and or Analogue based forecasting. This tool, "PUKKA" is an
analog selection tool that provides our clients with an access to 100
drug brands marketed in U.S. since 2005 up to 2012 with their
Qualitative and Quantitative data up to 2022.
Analogues play an important role in forecasting a new
product's market potential since there is no historical data that can be
referenced for the pipeline drug of interest.
The best analogs are those that are similar to the new
product in terms of disease type (Chronic/Acute), order of entry into
the market (by treatment and drug class), efficacy rate, dosage form,
dosing, route of administration, drug class, side effects,
contraindications, safety, drug cost per day, days of therapy, sales
data (historical and forecast) etc. However, it is almost impossible to
find analogs that match the product of interest in all of these
parameters. The solution is to study several analogs on common
attributes in order to create a forecast model for a new product.
The prime objective of this tool is to help our clients get
instant access to qualitative and quantitative (sales data for U.S. in
Millions) data for drug brands that they intend to study as analogs
while forecasting pipeline drugs.
We would like to express that this tool is not a mere
sales/forecast database tracking only top drug brands but is a tool that
captures all those drug brands that were approved by U.S. FDA from 2005
up to 2012 for single indications only. Since the tool's prime
objective is to help our clients forecast their pipeline drug through
analog based forecasting technique, we very carefully selected only
those drug brands approved for single indications till the last
historical year (2015) to ensure the analogs to be near accurate with
the drug attributes critical while choosing perfect analogs for
Drug brands with multiple approved indications record
inclusive sales thereby posing an unclear picture for single indication
which majority of the time leads to either exaggerated or underestimated
sales forecast for client's pipeline drug of interest.
Selection of appropriate set of analogs (at times one analog
or no analog) is dependent upon the selection criteria applied by
clients from the given list of attributes in the tool.
We request you to read the "Frequently Asked Questions"
section in this tool to clear most of your doubts/concerns. In case a
doubt persists our techno-commercial executive will be available round
the clock to respond to your further queries either via email or
telephone. You can mail us on email@example.com or call us on:
How it works?
After logging in for demo access, click on “View Demo” while the subscribers click on “Get Started. You will be directed to a page showing search criteria.
The user has to select at least one criterion and click “view Results” at the bottom to see the drug brands listed as per the selected criteria
Please click on the check boxes adjacent to the brands to view in detail – qualitative data, US Sales Data and Launch Year Wise Sales Data
“Launch Year Wise Data” tab shows sales performance of the selected brands right from year 1 of their launch till the last year of forecast period that is 2022 along with a dynamically generated chart for the selected drug brands
To re-visit the search criteria page from data view page, click on Refresh Search